Generative AI in Personalized Medicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Personalized Medicine Therapeutics (Pharmaceutical, Genomic Medicine, Devices), By Deployment Model (On-premises, Cloud Based), By End-User (Hospitals and Clinics, Ambulatory Surgical Centers, Others) By Region & Competition, 2021-2031F
The Global Generative AI in Personalized Medicine Market is anticipated to expand substantially, growing from USD 197.29 Million in 2025 to USD 798.52 Million by 2031, representing a CAGR of 26.24%. Generative AI within this sector leverages foundation models to process intricate genomic, phenotypic, and clinical data, thereby facilitating the development of unique molecular structures, synthetic patient cohorts, and tailored treatment strategies. This market growth is fundamentally driven by the urgent need to shorten pharmaceutical R&D timelines and the capacity of these algorithms to analyze unstructured multi-omics datasets for precision diagnostics. Reflecting this shift, the Pistoia Alliance reported in 2024 that 83% of life science professionals used generative AI in their research, highlighting an aggressive industry transition toward these advanced computational tools for therapeutic innovation.
However, despite this strong momentum, the market faces significant hurdles related to regulatory fragmentation and data compliance. The lack of consistent legal frameworks across major global regions creates uncertainty for multinational stakeholders trying to implement standardized, cross-border solutions. This absence of harmonized governance, along with inherent risks such as algorithmic bias and data privacy issues, creates a bottleneck that complicates the safe and scalable incorporation of generative AI into clinical workflows.
Market Driver
A primary engine for the Global Generative AI in Personalized Medicine Market is the reduction of pharmaceutical R&D costs and time-to-market, enabled by the technology's ability to optimize drug development processes. Generative algorithms are increasingly utilized to accelerate molecular interaction predictions and refine lead compounds, directly addressing the industry's need to lower the high attrition rates and expenses common in traditional discovery methods. These efficiencies are yielding rapid financial benefits; according to NVIDIA's 'State of AI in Healthcare and Life Sciences: 2025 Trends' survey from July 2025, 45% of healthcare and life sciences organizations using generative AI achieved a return on investment within 12 months, demonstrating the quick value realization these tools offer in research and clinical environments.
In parallel with these operational gains, the market is heavily supported by rising investment in public and private precision medicine initiatives. Venture capital and corporate funding are flowing into AI-native biotech firms that employ foundation models to scale tailored therapeutic development. For example, Isomorphic Labs announced in March 2025 that it raised $600 million in its first external funding round to advance its AI-driven drug design engine. This targeted enthusiasm is mirrored in broader financial trends; according to Mintz in March 2025, biotechnology AI companies drew approximately $5.6 billion in global venture capital during 2024, signaling robust confidence in the sector's potential to transform personalized care.
Market Challenge
Regulatory fragmentation and data compliance complexities serve as major barriers inhibiting the growth of the Global Generative AI in Personalized Medicine Market. The lack of a unified legal structure across key regions compels multinational stakeholders to manage a confusing array of conflicting data privacy laws and validation standards. This inconsistency generates considerable uncertainty, making it difficult for organizations to deploy standardized, cross-border solutions. As a result, legal risks associated with algorithmic bias and data handling stifle investment and delay the progression of generative AI tools from research laboratories to active clinical application.
The consequences of this uncertainty are clearly reflected in professional sentiment regarding technology adoption. In 2024, the American Medical Association noted that nearly 47% of physicians stressed the need for increased regulatory oversight of AI-enabled medical devices to ensure safety and establish trust. This call for clearer governance indicates that the current lack of harmonized regulations directly causes hesitation among medical practitioners. As long as these compliance bottlenecks remain, the scalability of personalized medicine initiatives will be restricted, thereby slowing the delivery of individualized treatment protocols.
Market Trends
A significant trend is the development of Domain-Specific Biological Large Language Models (Bio-LLMs), marking a shift from adapting general-purpose algorithms to using specialized architectures trained on extensive biological datasets. Unlike generic models, these Bio-LLMs are pre-trained on amino acid sequences, genomic strings, and chemical structures, allowing them to decode the underlying syntax of biological systems for more accurate target identification and personalized therapeutic design. This approach is gaining rapid traction as organizations aim for greater precision; according to Menlo Ventures' '2025: The State of AI in Healthcare' report from October 2025, 22% of healthcare organizations have implemented domain-specific AI tools, a seven-fold increase from the previous year that signals a maturing preference for purpose-built logic over generic foundation models.
Simultaneously, the Emergence of Multi-Modal Foundation Models for Holistic Patient Phenotyping is transforming diagnostics by integrating diverse data streams, such as clinical text, medical imaging, and omics profiles, into a single analytical framework. This convergence enables generative systems to create comprehensive patient representations that capture complex disease markers often missed by unimodal analysis, thereby refining patient stratification and individualized treatment selection. The industry's focus on processing complex visual and diagnostic data is intensifying; according to NVIDIA's July 2025 'State of AI in Healthcare and Life Sciences: 2025 Trends' survey, 71% of medical technology organizations identified medical imaging and diagnostics as a leading AI use case, highlighting the sector's commitment to leveraging multi-modal capabilities for deeper clinical insights.
Key Market Players
In this report, the Global Generative AI in Personalized Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Generative AI in Personalized Medicine Market.
Available Customizations:
Global Generative AI in Personalized Medicine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
However, despite this strong momentum, the market faces significant hurdles related to regulatory fragmentation and data compliance. The lack of consistent legal frameworks across major global regions creates uncertainty for multinational stakeholders trying to implement standardized, cross-border solutions. This absence of harmonized governance, along with inherent risks such as algorithmic bias and data privacy issues, creates a bottleneck that complicates the safe and scalable incorporation of generative AI into clinical workflows.
Market Driver
A primary engine for the Global Generative AI in Personalized Medicine Market is the reduction of pharmaceutical R&D costs and time-to-market, enabled by the technology's ability to optimize drug development processes. Generative algorithms are increasingly utilized to accelerate molecular interaction predictions and refine lead compounds, directly addressing the industry's need to lower the high attrition rates and expenses common in traditional discovery methods. These efficiencies are yielding rapid financial benefits; according to NVIDIA's 'State of AI in Healthcare and Life Sciences: 2025 Trends' survey from July 2025, 45% of healthcare and life sciences organizations using generative AI achieved a return on investment within 12 months, demonstrating the quick value realization these tools offer in research and clinical environments.
In parallel with these operational gains, the market is heavily supported by rising investment in public and private precision medicine initiatives. Venture capital and corporate funding are flowing into AI-native biotech firms that employ foundation models to scale tailored therapeutic development. For example, Isomorphic Labs announced in March 2025 that it raised $600 million in its first external funding round to advance its AI-driven drug design engine. This targeted enthusiasm is mirrored in broader financial trends; according to Mintz in March 2025, biotechnology AI companies drew approximately $5.6 billion in global venture capital during 2024, signaling robust confidence in the sector's potential to transform personalized care.
Market Challenge
Regulatory fragmentation and data compliance complexities serve as major barriers inhibiting the growth of the Global Generative AI in Personalized Medicine Market. The lack of a unified legal structure across key regions compels multinational stakeholders to manage a confusing array of conflicting data privacy laws and validation standards. This inconsistency generates considerable uncertainty, making it difficult for organizations to deploy standardized, cross-border solutions. As a result, legal risks associated with algorithmic bias and data handling stifle investment and delay the progression of generative AI tools from research laboratories to active clinical application.
The consequences of this uncertainty are clearly reflected in professional sentiment regarding technology adoption. In 2024, the American Medical Association noted that nearly 47% of physicians stressed the need for increased regulatory oversight of AI-enabled medical devices to ensure safety and establish trust. This call for clearer governance indicates that the current lack of harmonized regulations directly causes hesitation among medical practitioners. As long as these compliance bottlenecks remain, the scalability of personalized medicine initiatives will be restricted, thereby slowing the delivery of individualized treatment protocols.
Market Trends
A significant trend is the development of Domain-Specific Biological Large Language Models (Bio-LLMs), marking a shift from adapting general-purpose algorithms to using specialized architectures trained on extensive biological datasets. Unlike generic models, these Bio-LLMs are pre-trained on amino acid sequences, genomic strings, and chemical structures, allowing them to decode the underlying syntax of biological systems for more accurate target identification and personalized therapeutic design. This approach is gaining rapid traction as organizations aim for greater precision; according to Menlo Ventures' '2025: The State of AI in Healthcare' report from October 2025, 22% of healthcare organizations have implemented domain-specific AI tools, a seven-fold increase from the previous year that signals a maturing preference for purpose-built logic over generic foundation models.
Simultaneously, the Emergence of Multi-Modal Foundation Models for Holistic Patient Phenotyping is transforming diagnostics by integrating diverse data streams, such as clinical text, medical imaging, and omics profiles, into a single analytical framework. This convergence enables generative systems to create comprehensive patient representations that capture complex disease markers often missed by unimodal analysis, thereby refining patient stratification and individualized treatment selection. The industry's focus on processing complex visual and diagnostic data is intensifying; according to NVIDIA's July 2025 'State of AI in Healthcare and Life Sciences: 2025 Trends' survey, 71% of medical technology organizations identified medical imaging and diagnostics as a leading AI use case, highlighting the sector's commitment to leveraging multi-modal capabilities for deeper clinical insights.
Key Market Players
- Syntegra
- NioyaTech
- Saxon
- IBM Watson
- Microsoft Corporation
- Google LLC
- Tencent Holdings Ltd.
- Neuralink Corporation
- Johnson & Johnson
- OpenAI
- Oracle
In this report, the Global Generative AI in Personalized Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Generative AI in Personalized Medicine Market, By Personalized Medicine Therapeutics
- Pharmaceutical
- Genomic Medicine
- Devices
- Generative AI in Personalized Medicine Market, By Deployment Model
- On-premises
- Cloud Based
- Generative AI in Personalized Medicine Market, By End-User
- Hospitals and Clinics
- Ambulatory Surgical Centers
- Others
- Generative AI in Personalized Medicine Market, By Region
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Generative AI in Personalized Medicine Market.
Available Customizations:
Global Generative AI in Personalized Medicine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL GENERATIVE AI IN PERSONALIZED MEDICINE MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Personalized Medicine Therapeutics (Pharmaceutical, Genomic Medicine, Devices)
5.2.2. By Deployment Model (On-premises, Cloud Based)
5.2.3. By End-User (Hospitals and Clinics, Ambulatory Surgical Centers, Others)
5.2.4. By Region
5.2.5. By Company (2025)
5.3. Market Map
6. NORTH AMERICA GENERATIVE AI IN PERSONALIZED MEDICINE MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Personalized Medicine Therapeutics
6.2.2. By Deployment Model
6.2.3. By End-User
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Generative AI in Personalized Medicine Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Personalized Medicine Therapeutics
6.3.1.2.2. By Deployment Model
6.3.1.2.3. By End-User
6.3.2. Canada Generative AI in Personalized Medicine Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Personalized Medicine Therapeutics
6.3.2.2.2. By Deployment Model
6.3.2.2.3. By End-User
6.3.3. Mexico Generative AI in Personalized Medicine Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Personalized Medicine Therapeutics
6.3.3.2.2. By Deployment Model
6.3.3.2.3. By End-User
7. EUROPE GENERATIVE AI IN PERSONALIZED MEDICINE MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Personalized Medicine Therapeutics
7.2.2. By Deployment Model
7.2.3. By End-User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Generative AI in Personalized Medicine Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Personalized Medicine Therapeutics
7.3.1.2.2. By Deployment Model
7.3.1.2.3. By End-User
7.3.2. France Generative AI in Personalized Medicine Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Personalized Medicine Therapeutics
7.3.2.2.2. By Deployment Model
7.3.2.2.3. By End-User
7.3.3. United Kingdom Generative AI in Personalized Medicine Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Personalized Medicine Therapeutics
7.3.3.2.2. By Deployment Model
7.3.3.2.3. By End-User
7.3.4. Italy Generative AI in Personalized Medicine Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Personalized Medicine Therapeutics
7.3.4.2.2. By Deployment Model
7.3.4.2.3. By End-User
7.3.5. Spain Generative AI in Personalized Medicine Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Personalized Medicine Therapeutics
7.3.5.2.2. By Deployment Model
7.3.5.2.3. By End-User
8. ASIA PACIFIC GENERATIVE AI IN PERSONALIZED MEDICINE MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Personalized Medicine Therapeutics
8.2.2. By Deployment Model
8.2.3. By End-User
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Generative AI in Personalized Medicine Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Personalized Medicine Therapeutics
8.3.1.2.2. By Deployment Model
8.3.1.2.3. By End-User
8.3.2. India Generative AI in Personalized Medicine Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Personalized Medicine Therapeutics
8.3.2.2.2. By Deployment Model
8.3.2.2.3. By End-User
8.3.3. Japan Generative AI in Personalized Medicine Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Personalized Medicine Therapeutics
8.3.3.2.2. By Deployment Model
8.3.3.2.3. By End-User
8.3.4. South Korea Generative AI in Personalized Medicine Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Personalized Medicine Therapeutics
8.3.4.2.2. By Deployment Model
8.3.4.2.3. By End-User
8.3.5. Australia Generative AI in Personalized Medicine Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Personalized Medicine Therapeutics
8.3.5.2.2. By Deployment Model
8.3.5.2.3. By End-User
9. MIDDLE EAST & AFRICA GENERATIVE AI IN PERSONALIZED MEDICINE MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Personalized Medicine Therapeutics
9.2.2. By Deployment Model
9.2.3. By End-User
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Generative AI in Personalized Medicine Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Personalized Medicine Therapeutics
9.3.1.2.2. By Deployment Model
9.3.1.2.3. By End-User
9.3.2. UAE Generative AI in Personalized Medicine Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Personalized Medicine Therapeutics
9.3.2.2.2. By Deployment Model
9.3.2.2.3. By End-User
9.3.3. South Africa Generative AI in Personalized Medicine Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Personalized Medicine Therapeutics
9.3.3.2.2. By Deployment Model
9.3.3.2.3. By End-User
10. SOUTH AMERICA GENERATIVE AI IN PERSONALIZED MEDICINE MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Personalized Medicine Therapeutics
10.2.2. By Deployment Model
10.2.3. By End-User
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Generative AI in Personalized Medicine Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Personalized Medicine Therapeutics
10.3.1.2.2. By Deployment Model
10.3.1.2.3. By End-User
10.3.2. Colombia Generative AI in Personalized Medicine Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Personalized Medicine Therapeutics
10.3.2.2.2. By Deployment Model
10.3.2.2.3. By End-User
10.3.3. Argentina Generative AI in Personalized Medicine Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Personalized Medicine Therapeutics
10.3.3.2.2. By Deployment Model
10.3.3.2.3. By End-User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL GENERATIVE AI IN PERSONALIZED MEDICINE MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Syntegra
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. NioyaTech
15.3. Saxon
15.4. IBM Watson
15.5. Microsoft Corporation
15.6. Google LLC
15.7. Tencent Holdings Ltd.
15.8. Neuralink Corporation
15.9. Johnson & Johnson
15.10. OpenAI
15.11. Oracle
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL GENERATIVE AI IN PERSONALIZED MEDICINE MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Personalized Medicine Therapeutics (Pharmaceutical, Genomic Medicine, Devices)
5.2.2. By Deployment Model (On-premises, Cloud Based)
5.2.3. By End-User (Hospitals and Clinics, Ambulatory Surgical Centers, Others)
5.2.4. By Region
5.2.5. By Company (2025)
5.3. Market Map
6. NORTH AMERICA GENERATIVE AI IN PERSONALIZED MEDICINE MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Personalized Medicine Therapeutics
6.2.2. By Deployment Model
6.2.3. By End-User
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Generative AI in Personalized Medicine Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Personalized Medicine Therapeutics
6.3.1.2.2. By Deployment Model
6.3.1.2.3. By End-User
6.3.2. Canada Generative AI in Personalized Medicine Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Personalized Medicine Therapeutics
6.3.2.2.2. By Deployment Model
6.3.2.2.3. By End-User
6.3.3. Mexico Generative AI in Personalized Medicine Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Personalized Medicine Therapeutics
6.3.3.2.2. By Deployment Model
6.3.3.2.3. By End-User
7. EUROPE GENERATIVE AI IN PERSONALIZED MEDICINE MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Personalized Medicine Therapeutics
7.2.2. By Deployment Model
7.2.3. By End-User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Generative AI in Personalized Medicine Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Personalized Medicine Therapeutics
7.3.1.2.2. By Deployment Model
7.3.1.2.3. By End-User
7.3.2. France Generative AI in Personalized Medicine Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Personalized Medicine Therapeutics
7.3.2.2.2. By Deployment Model
7.3.2.2.3. By End-User
7.3.3. United Kingdom Generative AI in Personalized Medicine Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Personalized Medicine Therapeutics
7.3.3.2.2. By Deployment Model
7.3.3.2.3. By End-User
7.3.4. Italy Generative AI in Personalized Medicine Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Personalized Medicine Therapeutics
7.3.4.2.2. By Deployment Model
7.3.4.2.3. By End-User
7.3.5. Spain Generative AI in Personalized Medicine Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Personalized Medicine Therapeutics
7.3.5.2.2. By Deployment Model
7.3.5.2.3. By End-User
8. ASIA PACIFIC GENERATIVE AI IN PERSONALIZED MEDICINE MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Personalized Medicine Therapeutics
8.2.2. By Deployment Model
8.2.3. By End-User
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Generative AI in Personalized Medicine Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Personalized Medicine Therapeutics
8.3.1.2.2. By Deployment Model
8.3.1.2.3. By End-User
8.3.2. India Generative AI in Personalized Medicine Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Personalized Medicine Therapeutics
8.3.2.2.2. By Deployment Model
8.3.2.2.3. By End-User
8.3.3. Japan Generative AI in Personalized Medicine Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Personalized Medicine Therapeutics
8.3.3.2.2. By Deployment Model
8.3.3.2.3. By End-User
8.3.4. South Korea Generative AI in Personalized Medicine Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Personalized Medicine Therapeutics
8.3.4.2.2. By Deployment Model
8.3.4.2.3. By End-User
8.3.5. Australia Generative AI in Personalized Medicine Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Personalized Medicine Therapeutics
8.3.5.2.2. By Deployment Model
8.3.5.2.3. By End-User
9. MIDDLE EAST & AFRICA GENERATIVE AI IN PERSONALIZED MEDICINE MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Personalized Medicine Therapeutics
9.2.2. By Deployment Model
9.2.3. By End-User
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Generative AI in Personalized Medicine Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Personalized Medicine Therapeutics
9.3.1.2.2. By Deployment Model
9.3.1.2.3. By End-User
9.3.2. UAE Generative AI in Personalized Medicine Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Personalized Medicine Therapeutics
9.3.2.2.2. By Deployment Model
9.3.2.2.3. By End-User
9.3.3. South Africa Generative AI in Personalized Medicine Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Personalized Medicine Therapeutics
9.3.3.2.2. By Deployment Model
9.3.3.2.3. By End-User
10. SOUTH AMERICA GENERATIVE AI IN PERSONALIZED MEDICINE MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Personalized Medicine Therapeutics
10.2.2. By Deployment Model
10.2.3. By End-User
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Generative AI in Personalized Medicine Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Personalized Medicine Therapeutics
10.3.1.2.2. By Deployment Model
10.3.1.2.3. By End-User
10.3.2. Colombia Generative AI in Personalized Medicine Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Personalized Medicine Therapeutics
10.3.2.2.2. By Deployment Model
10.3.2.2.3. By End-User
10.3.3. Argentina Generative AI in Personalized Medicine Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Personalized Medicine Therapeutics
10.3.3.2.2. By Deployment Model
10.3.3.2.3. By End-User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL GENERATIVE AI IN PERSONALIZED MEDICINE MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Syntegra
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. NioyaTech
15.3. Saxon
15.4. IBM Watson
15.5. Microsoft Corporation
15.6. Google LLC
15.7. Tencent Holdings Ltd.
15.8. Neuralink Corporation
15.9. Johnson & Johnson
15.10. OpenAI
15.11. Oracle
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
